Rogers

Yahoo Finance • 4 days ago

Rogers and Lumen Shares Are Soaring, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after confidence in the artificial intelligence market was renewed, pushing both the S&P 500 and Nasdaq to new all-time intraday highs. The rebound was led by chipmaker Nv... Full story

Yahoo Finance • 4 days ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

BALA CYNWYD, Pa., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • 7 days ago

Roche receives CE Mark for AI-based Kidney Klinrisk Algorithm(1) and launches new comprehensive chronic kidney disease (CKD) algorithm panel

Roche, in collaboration with KlinRisk, Inc, has received CE-mark for the first AI-based risk stratification tool for assessment of progressive decline in kidney function.This tool will be launched as part of Roche’s new chronic kidney dise... Full story

Yahoo Finance • 10 days ago

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study1First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to he... Full story

Yahoo Finance • 10 days ago

Change in the Roche Board of Directors

F. Hoffmann-La Roche Ltd Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual Ge... Full story

Yahoo Finance • 10 days ago

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critica... Full story

Yahoo Finance • 10 days ago

Can Roche (SWX:ROG) Leverage Digital Diagnostics to Reinforce Its Long-Term Innovation Lead?

In recent days, Labcorp announced a collaboration with Roche to introduce FDA-cleared digital pathology slide scanners, while Roche separately unveiled the primary results for its sixth-generation high-sensitivity Troponin T test for heart... Full story

Yahoo Finance • 11 days ago

Roche commences tender offer for all shares of 89bio, Inc. for $14.50 per share in cash, plus a non-tradeable contingent value right for up to $6.00 per share in cash

Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14.50 per share in cash,... Full story

Yahoo Finance • 13 days ago

Data show Roche’s sixth-generation Troponin T test offers a new level of accuracy critical for diagnosing heart attacks

Recently granted CE Mark, the novel test delivers improved sensitivity and accuracy for faster and more reliable diagnosis in emergencies.The test helps clinicians quickly identify heart attack and rule out non-cardiac causes, ensuring pat... Full story

Yahoo Finance • 13 days ago

IG Group Holdings PLC: A Significant Exit by Invesco EQV European Equity Fund

This article first appeared on GuruFocus. Exploring the Strategic Moves in the Third Quarter of 2025 Invesco EQV European Equity Fund (Trades, Portfolio) recently submitted its N-PORT filing for the third quarter of 2025, shedding light... Full story

Yahoo Finance • 16 days ago

Roche Shares Dip 4% as Pharma Tariff Decision Looms: What Is the Stock Really Worth?

If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and... Full story

Yahoo Finance • 16 days ago

Trump demands Microsoft fire its president of global affairs over national security issues

[Attorney General Garland Holds Press Conference At Justice Department] Andrew Harnik/Getty Images News U.S. President Donald Trump has demanded Microsoft (NASDAQ:MSFT [https://seekingalpha.com/symbol/MSFT]) fire Lisa Monaco, its presiden... Full story

Yahoo Finance • 17 days ago

ROG Xbox Ally and ROG Xbox Ally X Now Available for Pre-Order in Canada

KEY POINTS Order now: Pre-orders for ROG Xbox Ally X and ROG Xbox Ally start at 8:00 p.m. ET on September 25, 2025, in select regionsSerious gen-on-gen performance: AMD Ryzen™ AI Z2 Extreme and Z2 A processors offer exceptional gaming exp... Full story

Yahoo Finance • 19 days ago

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

- Ocrevus subcutaneous maintains consistent benefit-risk profile after two years - - New late-breaking data confirms Ocrevus significantly reduces disability progression in adults with advanced PPMS - - One-year data reinforce that major... Full story

Yahoo Finance • 19 days ago

Roche presents new data for OCREVUS and fenebrutinib across broad patient populations at ECTRIMS 2025

OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults with advanced PPMSOne-year data reinforce that majority of infant... Full story

Yahoo Finance • 20 days ago

Roche (SWX:ROG): Assessing Valuation After Recent Quiet Uptrend in Share Price

If you have been watching Roche Holding (SWX:ROG), you might be wondering what to make of its recent run. The stock’s movement lately has caught the eye of many investors, not because of a headline-grabbing announcement or major setback, b... Full story

Yahoo Finance • 21 days ago

Positive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer

– evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in the post-CDK inhibitor setting, compared with standard of care plus everolimus – – The all-oral com... Full story

Yahoo Finance • 21 days ago

Positive phase III results show Roche’s giredestrant significantly improved progression-free survival in ER-positive advanced breast cancer

evERA met its co-primary endpoints; giredestrant plus everolimus demonstrated significant benefit in ITT and ESR1-mutated populations in post-CDK inhibitor setting, compared with standard of care plus everolimus The all-oral combination wa... Full story

Yahoo Finance • 24 days ago

CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma

Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four years1Subcutaneous Lunsumio has potential to substantially reduce treatment administration t... Full story

Yahoo Finance • 25 days ago

Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

First mass spectrometry-based test system for total 25-Hydroxyvitamin D to receive CLIA 'Moderate Complexity' designation in the U.S. Expands access to advanced testing with a fully automated, standardized workflow on the cobas® i 601 anal... Full story